MIS-C Treatment: Is glucocorticoid monotherapy enough for mild cases?
Küçük Resim Yok
Tarih
2024
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
W B saunders co-elsevier
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Background: The effectiveness of using only glucocorticoids (GCs) in mild multisystem in flammatory syndrome (MIS-C) cases was compared with combined treatment [GCs + Intravenous immune globulin (IVIG)]. Methods: This retrospective cohort study was conducted between June 1, 2020, and June 1, 2022, in a tertiary care center in Istanbul, Turkey. Clinical and investigational data of the MIS-C patients were analyzed. The patients were divided into two groups: those who received only GCs and those who received the GCs + IVIG combination. The primary outcome focused on assessing the deterioration of the patient's clinical condition, the occurrence of shock, admission to the pediatric intensive care unit (PICU), and the need for additional immunosuppressive medication. Secondary outcomes included evaluating the course of cardiovascular and infection-related complications observed at the one-year follow-up. Results: Ninety-seven MIS-C patients with a median age of 41 (3 - 214) months were enrolled. Fifty-six (57.7%) patients were male. All the patients had fever at admission with a temperature of 39 degrees C (37.5 degrees C -40.1 degrees C). Thirty-two patients (33%) had cardiac findings on echocardiography [left ventricular dysfunction ( n = 13, 13.5%), coronary artery involvement ( n = 11, 11.3%), and dilation of cardiac cavities and/or increased cardiac muscle thickness ( n = 8, 8.2%)]. Thirteen patients (13.5%) required intensive care. All patients received GCs [only GCs (group I; n = 65, 67%)], and 32 patients (33%) with severe manifestations and/or cardiac involvement received GCs + IVIG (group II). No mortality was observed. None of the patients had any complaints at the oneyear follow-up, and all echocardiography findings were normal. Conclusion: This study provides preliminary evidence that GC monotherapy is a safe treatment alternative for mild MIS-C cases without cardiac involvement. (c) 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
Açıklama
Anahtar Kelimeler
Multisysteminflammatory Syndrome in Chil-dren (MIS-C), Glucocorticoid Monotherapy, Cardiac Involvement
Kaynak
American journal of emergency medicine
WoS Q Değeri
Q1
Scopus Q Değeri
Q1
Cilt
83
Sayı
Künye
Sütçü, M., Kara, E. M., Yıldız, F., Gül, D., Yıldız, R., Yılmaz, D., ... & Özkaya, O. (2024). MIS-C Treatment: Is glucocorticoid monotherapy enough for mild cases?. The American Journal of Emergency Medicine, 83, 95-100.
